The Effect of Race/Ethnicity on the Accuracy of the 2001 Partin Tables for Predicting Pathologic Stage of Localized Prostate Cancer
Received 19 April 2007; accepted 10 August 2007.
Objectives
To test the accuracy of the 2001 Partin Tables in African American men who underwent radical prostatectomy at multiple centers throughout the United States.
Methods
We compiled a large multiethnic cohort of men (n = 3748) treated with radical prostatectomy at multiple sites, including all of the sites of the Department of Veterans Affairs–based Shared Equal Access Regional Cancer Hospital (SEARCH) database (n = 1524), Wayne State University (n = 1305), the University of Texas Health Science Center (n = 522), and the Henry Ford Hospital (n = 397). We evaluated the accuracy of the 2001 Partin Tables using area under the receiver operator characteristic curve (AUC) separately among African American and white men.
Results
African American men (n = 1188, 32%), despite being more likely to have clinical Stage T1c disease (56% versus 47%, chi-square P <0.001), had higher preoperative PSA values (9.1 versus 7.7 ng/mL, rank-sum P <0.001) and were more likely to have higher-grade disease on diagnostic biopsy (chi-square P = 0.005). Despite these differences in baseline clinical characteristics, the 2001 Partin Tables performed equally well in both racial groups. Specifically, there were no differences in the AUC for African American and white men for predicting organ-confined disease (AUC 0.73 versus 0.72; P = 0.56), extraprostatic extension (AUC 0.62 versus 0.62; P = 0.99), or seminal vesicle invasion (AUC 0.77 versus 0.79; P = 0.53).
Conclusions
These data lend further support to the idea that although baseline differences between the races existed that may underlie an overall more aggressive disease among African American men, for the individual patient, race is not valuable for prognostication.
aBarbara Ann Karmanos Cancer Institute, Detroit, Michigan
cThe University of Texas Health Science Center at San Antonio, San Antonio, Texas
dDepartment of Biostatistics and Research Epidemiology, Henry Ford Health System, Detroit, Michigan
eGreater Los Angeles Department of Veterans Affairs (VA) and University of California, Los Angeles, Los Angeles, California
fAugusta VA and Medical College of Georgia, Augusta, Georgia
gSan Francisco VA and University of California, San Francisco, San Francisco, California
hStanford University and Palo Alto VA, Palo Alto, California
iUniversity of Alabama Birmingham and Birmingham VA, Birmingham, Alabama
jDurham VA and Duke University, Durham, North Carolina
Reprint requests: Elisabeth I. Heath, M.D., Karmanos Cancer Institute, Department of Hematology and Oncology, Wayne State University, 4100 John R, 4 HWCRC, Detroit, MI 48201.
Supported by the Fund for Cancer Research, the Karmanos Cancer Institute (Detroit, Michigan), the U.S. Department of Defense, the U.S. Department of Veterans Affairs, the Georgia Cancer Coalition, the National Institutes of Health, and the American Urological Association Astellas Rising Star in Urology Award.
ABSTRACT